The patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXPart B: Patients must have either measurable disease or must be evaluable for MIBG response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions; patients with neuroblastoma in bone marrow only are not eligibleXx_NEWLINE_xXMust have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).Xx_NEWLINE_xXPatients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXAt least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXNo metastatic disease on cross-sectional imaging (according to Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 criteria)Xx_NEWLINE_xXPatients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXDocumented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment\r\n* NOTE: If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXPatients must have newly diagnosed, stage IIA – IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapyXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHistologically confirmed solid tumor malignancy that is metastatic or unresectable and have progressed on at least 1 prior therapy and for whom standard curative or palliative measures do not exist or are associated with minimal subject survival benefit. Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid Tumors (RECIST).Xx_NEWLINE_xXMeasurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be allowedXx_NEWLINE_xXAt least one measurable disease site (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) that has not been previously irradiatedXx_NEWLINE_xXMeasurable or evaluable disease using Response Evaluation Criteria in Solid TumorsXx_NEWLINE_xXPatients must have radiographically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteriaXx_NEWLINE_xXDisease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; disease that has undergone local therapy in the past 30 days is not considered measurable unless the investigator has documented progression despite the local therapy (for treatment phase)Xx_NEWLINE_xXMetastatic or unresectable disease and at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; NOTE: Nephrectomy or ablation of the primary tumor is allowed prior to enrollmentXx_NEWLINE_xXMeasurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts (measurable disease is not required for enrollment in the prostate cancer cohort):\r\n* RECIST version 1.1 criteria\r\n* Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria\r\n* RANO criteriaXx_NEWLINE_xXWomen with metastatic breast cancer, measurable or evaluable disease including bone metastasis only (as per the Response Evaluation Criteria in Solid Tumors [RECIST] v1.1)Xx_NEWLINE_xXMeasurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);Xx_NEWLINE_xXDose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (those undergoing pre-treatment resection must have imaging assessment after resection to determine measurability)\r\n* Previously irradiated sites of tumor may be considered measurable if there is radiographic progression at that site subsequent to the time of completing radiationXx_NEWLINE_xXMeasurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteriaXx_NEWLINE_xXOne or more metastatic tumors measurable per RECIST CriteriaXx_NEWLINE_xXPresence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXHave measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease per response evaluation criteria in solid tumors (RECIST) v1.1Xx_NEWLINE_xXMeasureable disease per response evaluation criteria (RECIST) v1.1Xx_NEWLINE_xXAt least 1 measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)Xx_NEWLINE_xXFor all dose expansion arms, participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Xx_NEWLINE_xXPatients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 =< 28 days prior to registrationXx_NEWLINE_xXParticipants enrolled in the Phase I portion must have evaluable disease; participants enrolled in the Phase II portion must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have evidence of radiographic disease progression within the past 12 months; progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not requiredXx_NEWLINE_xXHas measureable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.Xx_NEWLINE_xXDose expansion only: Subjects must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; this lesion must be outside a previously irradiated areaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXFor Part 1: Participant must have evaluable disease. For Part 2: Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXPresence of measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXEvaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXMust have at least one measurable lesion per irRECIST (immune-related Response Evaluation Criteria Criteria in Solid Tumors):Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Palpable lesions that are not measurable by radiologic or photographic evaluations may not be utilized as the only measurable lesion.Xx_NEWLINE_xXPatients must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1; tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapyXx_NEWLINE_xXHas at least one measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.Xx_NEWLINE_xXMust have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baselineXx_NEWLINE_xXPatients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)Xx_NEWLINE_xXEvaluable disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2), or by informative tumor marker(s).Xx_NEWLINE_xXMeasurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1Xx_NEWLINE_xXFor Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)Xx_NEWLINE_xXMeasurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigatorXx_NEWLINE_xXMeasurable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXParticipant must have at least one biopsiable lesion in the Phase 1 portion. In the Phase 2 part of the trial, participants must have either (a) at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or (b) at least one predominantly lytic bone lesion.Xx_NEWLINE_xXAt least 1 measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) meeting the following criteria:Xx_NEWLINE_xXMeasurable unresectable stage III or IV malignant melanoma and Response Criteria in Solid Tumors (RECIST), version 1.1Xx_NEWLINE_xXMeasurable disease per response evaluation criteria in solid tumors.Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXMust have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).Xx_NEWLINE_xXAt least one target lesion based on the evaluation criteria in solid tumors (RECIST 1.1).Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 that can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)Xx_NEWLINE_xXParticipants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; bone lesions are not considered measurable by definitionXx_NEWLINE_xXHas ?1 distant and/or discrete non-injected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography/magnetic resonance imaging (CT/MRI). This lesion must be measurable as defined by the response criteria used to assess the participant (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] for solid tumors or revised International Working Group [IWG] criteria for lymphomas).Xx_NEWLINE_xXPresence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPresence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is requiredXx_NEWLINE_xXAssessable disease status defined by Cheson (for lymphoma) or modified severity weighted assessment tool (mSWAT) (for mycosis fungoides [MF] and Sezary syndrome [SS]) criteria, or having measurable tumors defined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1) (for solid tumor)Xx_NEWLINE_xXHave measurable or non-measurable disease per RECIST 1.1 criteria for solid tumors and RANO criteria for HGGXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXThe patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPhase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1); baseline measurements must be obtained within 4 weeks prior to registrationXx_NEWLINE_xXAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiationXx_NEWLINE_xXPart A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXHave evidence of measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)Xx_NEWLINE_xXHave measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria presentXx_NEWLINE_xXThe patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).Xx_NEWLINE_xXMeasurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in dose escalation; measurable disease by RECIST 1.1 is required in dose expansionXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.Xx_NEWLINE_xXMeasurable disease is required per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1Xx_NEWLINE_xXPHASE I: Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXAt least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.Xx_NEWLINE_xXTumor size is measurable - measurable tumor criteria will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable metastatic melanoma with at least one lesion that is resectable for TIL generation and at least one other lesion that can be measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Patients with metastases limited to the bones are eligible.Xx_NEWLINE_xXSubjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1))Xx_NEWLINE_xXPatients must have measurable disease, documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or evaluable disease with a standard tumor marker (alpha-fetoprotein [AFP] and/or human chorionic gonadotropin [HCG]) greater than 10 times the upper limit of normalXx_NEWLINE_xXMeasurable disease is required according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPART I: Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria presentXx_NEWLINE_xXMeasurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1), modified RECIST or Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXHave measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; for example, this would include tumor in the lung, liver, and retroperitoneum; bone disease is difficult to follow and quantify and as a sole site would not be acceptableXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) and obtained by imaging within 30 days prior to being registered for protocol therapyXx_NEWLINE_xXAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI).Xx_NEWLINE_xXSubjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)Xx_NEWLINE_xXParticipants must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 that is amendable to biopsy.Xx_NEWLINE_xXSubjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.Xx_NEWLINE_xXMeasurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPatients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.Xx_NEWLINE_xXHave advanced cancer (metastatic, recurrent or locally advanced) and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria.Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)Xx_NEWLINE_xXMeasurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXThe participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1Xx_NEWLINE_xXSubjects must have received neoadjuvant chemotherapy (any number of cycles) with complete or partial response as assessed by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)Xx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteriaXx_NEWLINE_xXMeasurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 or pure lytic or mixed lytic-blastic bone lesionsXx_NEWLINE_xXHistologically and/or cytologically confirmed and radiographically measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 colorectal cancer with liver metastasis. Patients may have other sites metastatic disease.Xx_NEWLINE_xXMeasurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; stage IV or recurrent disease is requiredXx_NEWLINE_xXPresence of at least one lesion with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessmentXx_NEWLINE_xXMetastatic disease of at least two non-central nervous system (CNS) sites (including the index lesion to be treated) measurable by RECIST criteria with at least one site outside of the radiation field and evaluable by RECIST criteria for evaluation of responseXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients without measurable disease may be included on study after discussion with the sponsor, given that the primary endpoint of the study is Ki-67 of TIL (flow cytometry)Xx_NEWLINE_xXMeasurable and evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigatorXx_NEWLINE_xXConfirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST 1.1 (solid tumors) or Lugano (NHL):Xx_NEWLINE_xXMeasurable disease per response evaluation criteria in solid tumors (RECIST) v1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXParticipants must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXPatients must have evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXIn dose expansion, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by CT or magnetic resonance imaging (MRI)Xx_NEWLINE_xXSubjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Radiographic tumor assessment performed within 28 days of study inclusion.Xx_NEWLINE_xXHistological or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and be able to be followed over time by Immune related response criteria (irRC) for treatment decisionsXx_NEWLINE_xXA minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) \r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)Xx_NEWLINE_xXPatients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two metastatic lesions that meet criteria for SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treatedXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 limited to the abdomen and pelvisXx_NEWLINE_xXThe subject has a biopsy-proven diagnosis of adenocarcinoma of the pancreas (or recurrence of previously resected disease) with metastatic disease that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria presentXx_NEWLINE_xXSubjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), local or distantXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPresence of measurable disease by computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXAt least one measurable tumor lesion as defined by Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors [RECIST]) version (v)1.1 criteriaXx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1)Xx_NEWLINE_xXMeasurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Xx_NEWLINE_xXFor dose expansion phase, patients must have at least one site of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1)Xx_NEWLINE_xXAt least two sites of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; one of which must be amenable to treatment with SAR and accessible for a mandatory pre-treatment biopsy and a post-treatment biopsy at physician discretion; if a pulmonary nodule is being considered for SAR it must range in size from 1-5 cmXx_NEWLINE_xXHave measurable or evaluable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXSubjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1Xx_NEWLINE_xXMeasurable disease (either primary site and/or nodal disease) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteriaXx_NEWLINE_xXMetastatic disease that is evaluable radiologically by Response Evaluation Criteria in Solid Tumors (RECIST) or MD Anderson criteria, which will allow for bone-only diseaseXx_NEWLINE_xXMeasurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXTumor burden must be radiographically measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1, determined by investigator reviewXx_NEWLINE_xXMust have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.Xx_NEWLINE_xXDisease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXSubjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.Xx_NEWLINE_xXAt least 2 metastatic sites of which at least 1 must be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHas measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXDocumented disease recurrence/progression based on Gynecologic Cancer Intergroup (GCIG)-Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXSubjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria independent of the lesion irradiatedXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease with at least 1 unidimensional lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies and evaluable disease as assessed by bone scan and/or positron emission tomography (PET) scanXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignanciesXx_NEWLINE_xXPatients must have measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registrationXx_NEWLINE_xXHas measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)Xx_NEWLINE_xXFor patients enrolled in arm A dose level 4, arm A 14-patients expansion cohort, and arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable diseaseXx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXPatients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for patients with solid malignanciesXx_NEWLINE_xXProgressive disease based on radiological imaging within 12 months; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 would be used to assess measurable disease burdenXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPatients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registrationXx_NEWLINE_xXParticipants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens.Xx_NEWLINE_xXAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria that has not been previously irradiated and which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)Xx_NEWLINE_xXPatients must have measurable/evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteriaXx_NEWLINE_xXSubjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHave measurable or unmeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; baseline measurements and evaluations must be obtained within < 4 weeks of enrollment; disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapyXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; however, note that patients in Cohort 1 that have undergone an R0 resection will be eligible for the trialXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAll patients must have measurable lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 must have at least 1 tumour lesion amenable to biopsy, and must be medically fit and willing to undergo a biopsy before first treatment and, unless clinically contraindicated, after 6 weeks on therapyXx_NEWLINE_xXPatients with metastasis outside of the abdominal cavity; except\r\n* Disease outside of the abdomen that is non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria will be allowedXx_NEWLINE_xXAt least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAll patients must have evaluable disease as defined as:\r\n* Solid tumors must have a lesion evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1\r\n* Central nervous system tumors will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria\r\n* Leukemia patients must have > 10% blasts (or blast equivalent) in the bone marrowXx_NEWLINE_xXMeasurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1Xx_NEWLINE_xXAt least one measurable disease lesion according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1)Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) scan done within 30 days prior to study startXx_NEWLINE_xXMeasurable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHave a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) and have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; the target lesion(s) should also have bi-dimensional measurability for RECIST 1.1 evaluation on studyXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);Xx_NEWLINE_xXSubjects, including those in the dose-escalation portion of the study, must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; imagining must be within 28 days of trial enrollment\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site prior to trial enrollmentXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXSubjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMust have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST); the measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT unless progression at the site has occurredXx_NEWLINE_xXHave at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Xx_NEWLINE_xXA minimum of one measurable lesion defined as:\r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)Xx_NEWLINE_xXPHASE II SCLC: Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors, version (RECIST 1.1)Xx_NEWLINE_xXPresence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXEvaluable or measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); NOTE: Enrollment of patients with bone-only disease may be limited if we find we are not able to get adequate tissue for research correlates from bone biopsiesXx_NEWLINE_xXHave measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.Xx_NEWLINE_xXHave measurable or evaluable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesotheliomaXx_NEWLINE_xXPresence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable or evaluable indicator lesion(s) as defined by RECIST v1.1; patients without RECIST measurable disease will be eligible for enrollment to \Other\ cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup [GCIG] CA125 response criteria, positron emission tomography [PET] Response Criteria in Solid Tumors [PERCIST])Xx_NEWLINE_xXMeasurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1Xx_NEWLINE_xXMeasurable disease as defined by immune related Response Criterion (irRC) or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXAt least two measurable lesions (including the index lesion) according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version (v)1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients may have measurable disease only, non-measurable disease only, or both (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXThe patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST 1.1) criterionXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXPatient must have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXAt least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 on screening computed tomography (CT) or magnetic resonance imaging (MRI)Xx_NEWLINE_xXPatient has measurable disease by RECIST version 1.1 (solid tumors) or Lugano (lymphoma) criteria or evaluable or measureable disease by Macdonald criteria (rHGG).Xx_NEWLINE_xXEvaluable or measurable disease per Response Evaluation Criteria in Solid Tumors Version (RECIST)1.1Xx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXAt least one Response Evaluation Criteria in Solid Tumors (RECIST)-defined target lesion; patient must have documented disease progressionXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; tumor lesions previously irradiated or subjected to other loco-regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documentedXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registrationXx_NEWLINE_xXEvaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohortXx_NEWLINE_xXHas measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumorsXx_NEWLINE_xXSubject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXPresence of measurable recurrence, with Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease at the time of intervention consentXx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXSubjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; subjects with evaluable, but not measurable disease will be eligible for phase IXx_NEWLINE_xXPatients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable or evaluable disease; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans within 28 days of day 1, cycle 1; evaluable disease must include bone metastases (pleural effusions and ascites are not considered evaluable for this study)Xx_NEWLINE_xXPatients must have evaluable disease – defined as one of the following:\r\n* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR\r\n* Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXHas clinical response or stable disease for minimum of two months (three cycles of every three week chemotherapy or 8 weeks of weekly regimen, etc.) after receiving any prior chemotherapy for metastatic/recurrent disease; a minimum of two cycles (6-8 weeks) of chemotherapy is required to determine clinical response; per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, clinical response for measurable disease is defined as complete response (CR) or partial response (PR); for non-measurable disease only (i.e. bone metastasis, ascites, pleural effusion, and pathological lymph nodes >= 10 to < 15 mm short axis) is defined as persistence of one or more non-target lesion(s) and no increase in overall tumor burdenXx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXDisease progression based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria while the subject has been taking fulvestrant, and for which continuation of endocrine therapy would be appropriateXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXHistological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients with advanced, measurable metastatic EGA, by Response Evaluation Criteria In Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version [v]1.1)Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXProgressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator within the 12 months preceding study enrollmentXx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1Xx_NEWLINE_xXHave at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1)Xx_NEWLINE_xXAt least one measurable lesion as assessed by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXArms 1E, 2E, 3E: patients with at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 that have not been previously irradiatedXx_NEWLINE_xXPatients must have one target lesion to be utilized in order to assess response per Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXPatients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version (v)1.1\r\n* Lesions that have previously been treated with stereotactic radiosurgery (SRS) are excluded as measurable disease because distinction of radiation necrosis and tumor progression can be difficult in this setting and enlargement of the lesion may not necessarily mean progressionXx_NEWLINE_xXPresence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1Xx_NEWLINE_xXPatients must have at least one site of measurable disease (if applicable) (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for solid tumors or the appropriate disease classification/criteria for the target population)Xx_NEWLINE_xXThe target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteriaXx_NEWLINE_xXPatients are not required to have measurable disease by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as lesions in the pancreas are notoriously hard to measure radiographically; however, patients must have disease which is evaluable for resectionXx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; at least one measurable lesion needs to be outside the field of prior therapeutic radiation or has progressed after radiationXx_NEWLINE_xXPatients may have either measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAt least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors), or other disease specific response assessment criteria, as appropriate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXMeasurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesionXx_NEWLINE_xXHave measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or physical examXx_NEWLINE_xXA minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXHistologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteriaXx_NEWLINE_xXMeasurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXThe target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) and must have a maximum tumor volume of =< 100 cm^3Xx_NEWLINE_xXStage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial– if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapyXx_NEWLINE_xXPatients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant; tumor marker increase alone is not sufficient to diagnose disease progressionXx_NEWLINE_xXDocumented progression of disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as any progression that requires a change in treatment, prior to randomizationXx_NEWLINE_xXMeasurable disease, that is, presenting with at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).Xx_NEWLINE_xXParticipants must have measurable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (>=) 10 millimeter (mm) in the long axis or extrapelvic lymph node of >=15 mm in the short axis)Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team. Target tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;Xx_NEWLINE_xXAt least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRIXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, bone only metastatic disease may be allowed on approval from study principal investigator (PI)Xx_NEWLINE_xXSubject has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumor lesions situated in previously irradiated areas are considered measurable if progression has been demonstrated in such lesionsXx_NEWLINE_xXPatients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXHas measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:Xx_NEWLINE_xXAt least one evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1criteria; (patients whose only nodal disease is cystic and not positron emission tomography [PET]-avid are not eligible)Xx_NEWLINE_xXSubjects who have measurable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.Xx_NEWLINE_xXAt least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in contrast enhanced (unless contraindicated) CT or MRI.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IIIB or IV NSCLC with radiographic proof of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXEvaluable disease for dose escalation, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for dose expansionsXx_NEWLINE_xXAt least two sites of disease that are measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXRENAL COHORT: Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria in at least one site that is not the site for planned surgical resection or serial biopsyXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigatorXx_NEWLINE_xXPhase II only: Must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMetastatic disease in at least two distinct lesions (including the index lesion to be treated) with at least one site outside of the radiation field and evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation of responseXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumorsXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or at least one site of disease must be uni-dimensionally measurable as per RECIST 1.1. All radiology studies must be performed within 28 days prior to registrationXx_NEWLINE_xXHistologically proven metastatic pancreatic or colorectal adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors, within 28 days prior to registrationXx_NEWLINE_xXRadiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXBi-dimensionally measurable disease by radiographic imaging (computed tomography [CT] scan) that represents at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatmentXx_NEWLINE_xXAt least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have a clinically measurable primary oropharyngeal tumor, defined as measuring >= 1 cm by spiral computed tomography (CT), per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and/or by clinical examinationXx_NEWLINE_xXAt least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXParticipant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per the Central Radiographic Assessment Committee (CRAC).Xx_NEWLINE_xXPatients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).Xx_NEWLINE_xXMeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 and >= 1 site safe for biopsyXx_NEWLINE_xXMeasurable or evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Xx_NEWLINE_xXSubjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 or elevated tumor markers (human chorionic gonadotropin [hCG], alpha-fetoprotein [AFP])\r\n* Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsyXx_NEWLINE_xXPatients must have measurable recurrence or metastases, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standardXx_NEWLINE_xXMeasurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesotheliomaXx_NEWLINE_xXSubjects with extracranial disease must have evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); subjects affected by glioma must have evaluable disease by Response Assessment in Neuro-Oncology Criteria (RANO) criteriaXx_NEWLINE_xXAt least one measureable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXPresence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (not required for Part 1); presence of evaluable OR measurable disease for Part 1Xx_NEWLINE_xXParticipants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXCA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable diseaseXx_NEWLINE_xXHave 2 or more measurable sites of disease as defined by either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or cutaneous lesions at least 1 cm in greatest dimensionXx_NEWLINE_xXPatients with confirmed diagnosis of ECD that are asymptomatic and with no visceral involvement are not eligible for this trial (patients with no target lesions as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)Xx_NEWLINE_xXMeasurable disease per disease specific Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1-patients with bone as their only site of disease will not be eligibleXx_NEWLINE_xXMust have a minimum of 3 radiographically distinct (> 1.5 cm) lesions measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of study enrollment (> 5 preferred)\r\n* A maximum of 2 metastases per treated organ may be targeted for HD-XRT, but must be separated by more than 5 cm of normal tissue\r\n* At least 2 non-irradiated lesions are required for systemic response assessmentsXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXParticipants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or evaluable cancer via cancer antigen (CA)125 Gynecologic Cancer Intergroup (GCIG) criteriaXx_NEWLINE_xXSubjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease, i.e., at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria only for expansion cohortsXx_NEWLINE_xXPatients enrolled in the dose expansion phase must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors or measurable nodal disease at baseline as defined by Cheson criteria for lymphomaXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHistologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be usedXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable or evaluable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBMXx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1Xx_NEWLINE_xXEvaluable disease, as follows:\r\n* For phase IA dose escalation: have the presence of any evaluable disease, including bone metastases, effusion, or cystic metastases\r\n* For phase IB extension only: have progressive and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1)Xx_NEWLINE_xXAll sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable or non-measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration (Phase I)Xx_NEWLINE_xXAll patients must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have at least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)Xx_NEWLINE_xXMeasurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or non-measurable disease, with measurement obtained within 4 weeks of registrationXx_NEWLINE_xXNon-measurable and/or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or abnormal cancer antigen (CA)-125 to levels (in patients with ovarian cancer) at least 1.5 x normal documented by two independent measurements at least 4 weeks apartXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registrationXx_NEWLINE_xXPatients with recurrence must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1); tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapyXx_NEWLINE_xXAt least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXThe disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors 1.1.Xx_NEWLINE_xXParticipants in the randomized portion of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.Xx_NEWLINE_xXHas at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor.Xx_NEWLINE_xXAt least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment (certain exceptions may apply)Xx_NEWLINE_xXPresence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.Xx_NEWLINE_xXMeasurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.Xx_NEWLINE_xXHave measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1Xx_NEWLINE_xXMeasurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Xx_NEWLINE_xXPatients in the phase II portion must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; previously irradiated sites can be included if there is documented progression of disease in that site; patients in the phase I portion do not require measurable disease by RECIST 1.1 criteriaXx_NEWLINE_xXPatients who have measurable disease must have at least one “target lesion” to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumors within a previously irradiated field will be designated as “non-target” lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapyXx_NEWLINE_xXPatients must have disease that can be evaluated radiographically, this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXmeasurable and/or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXDisease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXHave measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECISTXx_NEWLINE_xXMeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteriaXx_NEWLINE_xXAt least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiationXx_NEWLINE_xXPatients must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 9.3 criteriaXx_NEWLINE_xXParticipants must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXHas at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXSubjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXMeasurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXDose Expansion Phase: at least one measureable lesion as defined by RECIST [Response Evaluation Criterion in Solid Tumors] version 1.1.Xx_NEWLINE_xXMeasurable disease using clinically appropriate criteria for the type of malignancy, RECIST version 1.1 for solid tumors and Cheson 2007 for lymphomaXx_NEWLINE_xXEvidence of measurable disease at screening as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXParticipant must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.Xx_NEWLINE_xXBoth measurable as well as non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be allowedXx_NEWLINE_xXAs defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro Oncology (RANO) criteria for glioblastoma:Xx_NEWLINE_xXPatient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelinesXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria (for solid tumors) or equivalent criteria (for patients with non-solid tumor malignancies)Xx_NEWLINE_xXMeasurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1.Xx_NEWLINE_xXEvaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMust have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesotheliomaXx_NEWLINE_xXSubject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).Xx_NEWLINE_xXAt least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXHave measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).Xx_NEWLINE_xXHas measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendorXx_NEWLINE_xXHas measurable disease at baseline based on Response Evaluation Criteria is Solid Tumors (RECIST) 1.1 as determined by the central imaging vendorXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1Xx_NEWLINE_xXHave evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria within 3 months prior to study enrollment; if the patient was receiving a prior line of systemic therapy, he/she should have evidence of disease progression on that line of treatment prior to enrollmentXx_NEWLINE_xXMeasurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).Xx_NEWLINE_xXMeasureable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1Xx_NEWLINE_xXHave measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only diseaseXx_NEWLINE_xXPatients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registrationXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) (Response Evaluation Criteria in Solid Tumors [RECIST] criteria 1.1)Xx_NEWLINE_xXHave measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXAll sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or bone-only non measurable disease.Xx_NEWLINE_xXResponse expansion/RP2D expansion/ FE Cohort subjects: disease progression on or was intolerant to prior EGFR TKI; activating mutation as above AND T790M mutation; tumor sample subsequent to EGFR TKI is available for central testing; at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Inclusion Criteria for Exon 20 cohort:Xx_NEWLINE_xXHave either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).Xx_NEWLINE_xXMeasurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatmentXx_NEWLINE_xXA minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)Xx_NEWLINE_xXMeasurable or evaluable disease will be included as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXExpansion Phase only: Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009), ie, has at least one measurable lesionXx_NEWLINE_xXMeasurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteriaXx_NEWLINE_xXMeasurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only diseaseXx_NEWLINE_xXSubject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Xx_NEWLINE_xXA minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)Xx_NEWLINE_xXAt least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiationXx_NEWLINE_xXThe patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the above pathology criteriaXx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXPatients must have disease (measurable or non-measurable acceptable) according to Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 criteriaXx_NEWLINE_xXDisease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXMeasurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAll sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or any other baseline prerequisite for the assessment of the principal judgement criteriaXx_NEWLINE_xXHave a diagnosis of NSCLC with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).Xx_NEWLINE_xXHave the presence of measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXSubjects with solid tumors, with the exception of castration-resistant prostate cancer (CRPC), must demonstrate measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXParticipant has radiographically-documented measurable disease, as per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).Xx_NEWLINE_xXPatients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) that is accessible to biopsyXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXPresence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009).Xx_NEWLINE_xXMeasurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).Xx_NEWLINE_xXParticipants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXParticipants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXTarget or non-target lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1Xx_NEWLINE_xXThe participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).Xx_NEWLINE_xXEvaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for peritoneal mesothelioma, and modified RECIST for pleural mesotheliomaXx_NEWLINE_xXSubject has radiological documented measurable disease (ie, at least one measureable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1).Xx_NEWLINE_xXSubjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPart 2 only: Measureable tumor (Response Evaluation Criteria In Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAll patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, computed tomography (CT) scans or magnetic resonance imagings (MRIs) used to assess the measurable disease must have been completed within 28 days prior to study drug initiationXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; if no measurable disease is present, patients should have assessable disease such as pleural effusion, ascites, with cancer antigen 125 (CA125) Gynecological Cancer Intergroup (GCIG) criteriaXx_NEWLINE_xXMeasurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a lesion in a previously irradiated area is ineligible to be considered as measurable disease unless there is objective evidence of progression of the lesion prior to study enrollmentXx_NEWLINE_xXAt least one measureable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXSubject must have at least 1 unidimensional measurable NSCLC lesion on a Computerized Tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version 1.1).Xx_NEWLINE_xXMeasurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteriaXx_NEWLINE_xXPatients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumorsXx_NEWLINE_xXAt least one \target lesion\ to be used to assess response, as defined by RECIST 1.1 criteria;Xx_NEWLINE_xXMeasurable or evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1 (v 1)Xx_NEWLINE_xXHave measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1)Xx_NEWLINE_xXMeasurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable tumor (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)Xx_NEWLINE_xXMust have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease by computed tomography (CT) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 to evaluate responseXx_NEWLINE_xXMeasurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiatedXx_NEWLINE_xXPatients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])Xx_NEWLINE_xXNo disease progression (i.e. stable disease [SD] or better response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) at the completion of chemotherapy.Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, which includes locoregional lesions (not amenable to curative surgery and/or radiation) and distant metastatic lesionsXx_NEWLINE_xXAt least 1 lesion on a computed tomography (CT) scan that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1.Xx_NEWLINE_xXPatients must have at least one tumor lesion that meets the following criteria: the lesion can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumor (RECIST)Xx_NEWLINE_xXMeasurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXParticipants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXSubjects must have entered the Maintenance Phase and are under ongoing maintenance treatment or subjects who stopped maintenance treatment because of a complete response (CR) or subjects with an initial partial response (PR) or CR or at least 3 months of stable disease (SD) on tumor assessment and who subsequently have a confirmed and documented disease progression (per immune-related Response Evaluation Criteria in Solid Tumors [RECIST] criteria)Xx_NEWLINE_xXMeasurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesionXx_NEWLINE_xXOne or more measurable metastatic tumors measurable on CT san per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 ), excluding the primary lesion.Xx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)Xx_NEWLINE_xXProgressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteriaXx_NEWLINE_xXPatients must have at least one site of measurable disease (if applicable) (per RECIST for solid tumors or the appropriate disease classification/criteria for the target population)Xx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXProgressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.Xx_NEWLINE_xXMeasurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAt least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPatients with measurable or non-measurable metastatic disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 guidelines or evaluable disease; bone metastases must be evaluableXx_NEWLINE_xXMeasurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXHistory of previous response to EGFR-TKI, defined as either a PR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or at least six months without progressive disease as a result of EGFR-TKI therapyXx_NEWLINE_xXPatients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have a primary or metastatic lesion measurable in at least one dimension by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 within 4 weeks prior to entry of studyXx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1Xx_NEWLINE_xXSubjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesionXx_NEWLINE_xXPatients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in the previously irradiated fieldXx_NEWLINE_xXSubjects must have measurable or evaluable disease; disease sites that are evaluable for progression but not measurable per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 include:\r\n* Bone lesions\r\n* Previously irradiated lesions\r\n* Cutaneous manifestations (non-discrete lesions only)Xx_NEWLINE_xXAt least one measurable lesion according to response evaluation criteria in solid tumours version 1.1Xx_NEWLINE_xXMust have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXIn continuous complete or partial remission or stable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) after standard first-line treatment.Xx_NEWLINE_xXMeasurable disease by (Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) or evaluable diseaseXx_NEWLINE_xXEvidence of unidimensionally measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXAs defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors [RECIST 1.1];Xx_NEWLINE_xXPatient on the dose-escalation portion of the trial must have evaluable disease, defined as either measurable (by Response Evaluation Criteria in Solid Tumors [RECIST]) or non-measurable disease (e.g. bone mets, pleural effusion or lymphangitic spread); measureable disease is required for patients in the expanded RP2D cohortXx_NEWLINE_xXMeasurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPresence of at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1Xx_NEWLINE_xXHave the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapyXx_NEWLINE_xXPatients must have measurable disease as per the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1)Xx_NEWLINE_xXPatients may be registered on study prior to completing all chemotherapy but only those having a response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria after 3 to 6 cycles of first-line chemotherapy may proceed on study with SBRT/radiation therapy (RT) treatmentXx_NEWLINE_xXEXPANSION COHORT ONLY: Participants must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 besides the tumor that is expected to be radiated; bony lesions without soft tissue component are not measurable lesionsXx_NEWLINE_xXPatient has at least one measurable nodal lesion (>= 2 cm) according to Response Evaluation Criteria in Lymphoma (RECIL) criteriaXx_NEWLINE_xXMeasurable (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) indicator lesion not previously irradiatedXx_NEWLINE_xXMeasurable and/or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria; bone only disease is allowedXx_NEWLINE_xXHas measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by CT or MRI scan within 28 days prior to enrollment.Xx_NEWLINE_xXPatients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXPatient must have at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or magnetic resonance imaging (MRI) which will not be irradiatedXx_NEWLINE_xXAt least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiatedXx_NEWLINE_xXMeasurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) 1.1 mRECIST or elevated AFPXx_NEWLINE_xXAt least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST).Xx_NEWLINE_xXMust have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapyXx_NEWLINE_xXAll patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1Xx_NEWLINE_xXPart 2/Dose Expansion Only: Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) outside of any prior radiation field.Xx_NEWLINE_xXPatient must have at least one target lesion to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistent disease at least 90 days following completion of radiation therapyXx_NEWLINE_xXPatients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1Xx_NEWLINE_xXHave at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1Xx_NEWLINE_xXHave at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CRPC participants may be enrolled with objective evidence of disease as per Prostate Cancer Working Group (PCWG2) criteriaXx_NEWLINE_xXMeasurable indicator lesion by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXSubject has at least 1 measureable lesion (not including any lesion that was irradiated) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXPatients may have no evidence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have measurable disease; CA-125 and other available markers will be obtainedXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1.Xx_NEWLINE_xXSubjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXEvaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).Xx_NEWLINE_xXPatients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).Xx_NEWLINE_xXMeasurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) [Groups 1, 2 of Part A and Group 3 of Part B] Inclusion Criteria Part A: MADXx_NEWLINE_xXEligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Xx_NEWLINE_xXPatients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1Xx_NEWLINE_xXAt least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must have measureable disease at screening by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).Xx_NEWLINE_xXPatients must have at least one uni-dimensional measurable lesion by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. (applicable only in Phase 2)Xx_NEWLINE_xXAt least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXDisease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility) and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXParticipants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registrationXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesionXx_NEWLINE_xXPatients must have evaluable disease; measurable disease is not required; however, if measurable disease is present, it is defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1; furthermore, if only evaluable disease is present, a relevant tumor marker (per investigator discretion) must be >= 2 times upper limit of normal (ULN) at baseline, and can be used as a response indicatorXx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease defined as 1 or more target lesions according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)Xx_NEWLINE_xXHave at least 1 extracranial metastasis that is amenable to radiation and at least 1 other site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. At least one measurable lesion must be in the lungs.Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteriaXx_NEWLINE_xXMeasurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)Xx_NEWLINE_xXRadiologically measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXPatients must have at least one \target lesion\ to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST); tumors within a previously irradiated field will be designated as \non-target\ lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapyXx_NEWLINE_xXPatient’s disease must be bi-dimensionally measurable by caliper or radiological method as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria; for subjects with a single lesion, archived tissue must be available for research analysis; multiple superficial melanoma lesions must have an aggregate total diameter of >=10 mmXx_NEWLINE_xXSubjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXHave at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Xx_NEWLINE_xXMeasurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.Xx_NEWLINE_xXHistologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable and/or evaluable disease based on Response Evaluation Criteria in Solid\n             Tumors (RECIST version 1.1)Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) For multiple myeloma only:Xx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors v1.1Xx_NEWLINE_xXPatients must have measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease per response evaluation criteria in solid tumors (RECIST) v1.1Xx_NEWLINE_xXHas measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXFor escalation: documentation by established staging studies or clinical examination to have measurable or non-measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXPatient must have previously progressed on abiraterone (either by PCWG2 criteria or Response Evaluation Criteria in Solid Tumors [RECIST] criteria)Xx_NEWLINE_xXProgression in measurable disease Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the time of study entryXx_NEWLINE_xXAll patients enrolled will be required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation fieldXx_NEWLINE_xXRadiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) on imaging studies CTXx_NEWLINE_xXProgressive disease as demonstrated by a rising PSA (at least two determinations) prior to study entry, and/or radiographic evidence of tumor progression in soft tissue according to modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria or identification of new lesions by bone scan (i.e., >= 2 new lesions)Xx_NEWLINE_xXMeasurable (Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) indicator lesion not previously irradiatedXx_NEWLINE_xXAt least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXSubjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMetastatic or advanced breast cancer that is evaluable OR metastatic or advanced breast cancer that is measurable for response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXAt least one target lesion that has not been treated with local therapy and is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXEvaluable disease or disease measurable per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Xx_NEWLINE_xXPreviously treated with trametinib on Arm A and experienced objective disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXRadiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXPresence of either evaluable disease or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); baseline measurements must be obtained within 4 weeks prior to initiating therapy; at least 1 of the tumor sites must be amenable to surgical or core biopsyXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Xx_NEWLINE_xXPatients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 or non-measurable tumorsXx_NEWLINE_xXThe subject has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Xx_NEWLINE_xXSubjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)Xx_NEWLINE_xXPatients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)Xx_NEWLINE_xXEvaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1Xx_NEWLINE_xXPatients with measurable or evaluable disease according to the response evaluation criteria in solid tumorsXx_NEWLINE_xXMetastatic disease documented on diagnostic imaging studies with measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXMeasurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXSoft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXRadiographically measurable disease; measurable disease is defined as disease that can be assessed with 2-dimensional measurements on a cross-sectional imaging; minimum lesion size is 2 cm in greatest diameter as per Response Evaluation Criteria in Solid Tumors (RECIST) criteriaXx_NEWLINE_xXPatients must show evidence of objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1 on scans within the 6 month period immediately preceding enrollment; both scans used to determine disease progression should have been obtained within this 6-month periodXx_NEWLINE_xXMeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXPatients must have measurable or evaluable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPresence of at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable or evaluable disease according to RECIST for solid tumors or according to IWRC for NHL tumorsXx_NEWLINE_xXDisease that is measurable per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1Xx_NEWLINE_xXMeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXSubjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXParticipants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scansXx_NEWLINE_xXDocumented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M diseaseXx_NEWLINE_xXPatients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients enrolled in the dose expansion phase must have at least one measurable lesion as defined by RECIST criteria for solid tumors or Measurable nodal disease at baseline as defined by Cheson criteria for Lymphoma.Xx_NEWLINE_xXMeasurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (for phase II part only)Xx_NEWLINE_xXThe participant has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines.Xx_NEWLINE_xXPatients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiationXx_NEWLINE_xXMust have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXHistologically confirmed, measurable or evaluable disease; if disease is measurable Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be usedXx_NEWLINE_xXPresence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1Xx_NEWLINE_xXPatients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure responseXx_NEWLINE_xXPatients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXPatients must have computed tomography (CT) measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)Xx_NEWLINE_xXPhase Ib: Have evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteriaXx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at the time of study entryXx_NEWLINE_xXDocumented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment; NOTE: if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST)Xx_NEWLINE_xXCutaneous tumor deposits that, in the opinion of the investigator are amenable to sequential biopsies for correlative analyses; in addition to these, all patients must have measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)Xx_NEWLINE_xXAt least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Xx_NEWLINE_xXParticipants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:Xx_NEWLINE_xXHave evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 2 (PCWG2) criteriaXx_NEWLINE_xXMeasurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteriaXx_NEWLINE_xXPatients must have measurable or evaluable/non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients with bone only disease are not eligible; NOTE: for patients with metastatic disease in the liver, tumor burden should not be deemed significant (e.g., to no more than 30% of total liver volume as assessed by local review/investigator)Xx_NEWLINE_xXPatients must have either measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or evaluable disease (non-measurable lesions) outside irradiated field on computed tomography (CT)/magnetic resonance imaging (MRI)Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Xx_NEWLINE_xXMeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1, see Section 9)Xx_NEWLINE_xXDisease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG); patients with effusion only disease or disease only in the liver are not eligible for the studyXx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)Xx_NEWLINE_xXMeasurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Xx_NEWLINE_xXAt least one lesion measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0: > 2 cm in diameter to avoid PET partial volume effectsXx_NEWLINE_xXHave measurable disease based on RECIST version (v) 1.1 for solid tumorsXx_NEWLINE_xXDisease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG). Patients with effusion only disease or disease only in the liver are not eligible for the study.Xx_NEWLINE_xXMust have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 regardless of disease stage (e.g. localized, locally advanced, or metastatic)Xx_NEWLINE_xXDisease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a mass of greater than 1 cm in the long axis and/or other tumor response criteria from an MSKCC institutional review board (IRB)-approved clinical research protocol; NOTE: study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitmentXx_NEWLINE_xXDisease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol; NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitmentXx_NEWLINE_xXPatients must have measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXEligible adult patients currently meeting inclusion criteria and will be treated with an investigational or recently approved therapeutic agent at HCI; the patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; RECIST imaging must be current and have been obtained within 30 days prior to the baseline imaging sessionXx_NEWLINE_xXHas measureable disease by Response Evaluation Criteria In Solid Tumors (RECIST)Xx_NEWLINE_xXSubjects must have measurable disease by CT or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; to comply with PET Response Criteria in Solid Tumors (PERCIST) criteria, subjects should have at least one lesion measuring at least 2 cm in the longest diameterXx_NEWLINE_xXPresence of at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)Xx_NEWLINE_xXSubjects are required to have measurable disease that has progressed through prior therapy and that includes a non-hepatic lesion for imaging that is >= 1.5 cm, as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST)Xx_NEWLINE_xXSubjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXAt least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.Xx_NEWLINE_xXHas measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentationXx_NEWLINE_xXMeasurable disease according to RECIST v.1.1 (or Choi criteria and/or EORTC metabolic response criteria for solid tumors, in the case of GIST); orXx_NEWLINE_xXMeasurable disease according to Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)Xx_NEWLINE_xXHas measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by local radiology review.Xx_NEWLINE_xXHave presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).Xx_NEWLINE_xXHave measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Xx_NEWLINE_xXRecurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination. In phase II, measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 is mandated. In phase Ib, patients with or without measurable disease are eligible.Xx_NEWLINE_xXSubject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1Xx_NEWLINE_xX